Automated, miniaturized and accelerated drug discovery: AMADEUS

AMADEUS is an automated platform for rapid, sustainable drug discovery that synthesizes thousands of small molecules daily, optimizing processes through AI to reduce costs and enhance accessibility.

Subsidie
€ 3.409.401
2024

Projectdetails

Introduction

The mantra ‘Automation + Miniaturization = Acceleration’ is successfully applied in many research areas and technologies, but not in synthetic chemistry, which is largely believed to be not automatable. However, with the potential to accelerate discoveries while flattening costs, increase safety, streamline data generation, enhance reproducibility, and lower the environmental footprint, automation and miniaturization are two promising approaches to synthesis and are worthwhile to invest in.

Project Overview

I will engineer and validate a comprehensive technology platform, AMADEUS (Automated, MiniAturizeD, and acceleratEd drUg diScovery), which is able to synthesize in a fully autonomous manner thousands of small molecules per day in nano- or picolitre volumes, based on hundreds of chemistries, efficiently screened and optimized for properties using artificial intelligence.

Technical Details

The AMADEUS process will be achieved by interfacing four different modules:

  1. A synthetic part based on acoustic droplet ejection technology.
  2. A UPLC MS QC and purification module.
  3. A flexible mounted screening unit.
  4. A machine learning module that retrieves and processes all relevant synthesis, QC, and screening ‘real-time’ data and automatically guides the iterative optimization cycle.

Applications

AMADEUS will be showcased with several medicinal chemistry, catalysis, and organic chemistry projects.

Challenge to Traditional Processes

With my project, I want to challenge the early drug discovery process, which for over 50 years in pharma companies around the world has (almost uniformly) been pursued and comprises two blocks:

  1. A high throughput screen relying on millions of curated and stored compounds.
  2. The subsequent hit-to-lead optimization phase often called the ‘design, make, test cycle’.

Impact

AMADEUS will contribute to the accelerated discovery of drugs for unmet medical needs and ultimately reduce drug costs for patients.

Sustainability

AMADEUS is a highly sustainable synthesis platform.

Democratization of Drug Discovery

AMADEUS will help democratize drug discovery.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 3.409.401
Totale projectbegroting€ 3.409.401

Tijdlijn

Startdatum1-1-2024
Einddatum31-12-2028
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • UNIVERZITA PALACKEHO V OLOMOUCIpenvoerder

Land(en)

Czechia

Vergelijkbare projecten binnen European Research Council

ERC Proof of...

High-throughput combinatory drugs testing on in vitro 3D cells model platform

The project aims to develop a microfluidic platform for high-throughput screening of drug combinations in 3D cultures to enhance drug discovery and identify synergistic therapies for breast cancer.

€ 150.000
ERC Synergy ...

Deep learning analysis of imaging and metabolomic data to accelerate antibiotic discovery against antimicrobial resistance

AI4AMR aims to revolutionize antibiotic discovery by using advanced AI and multi-dimensional data analysis to identify novel antibiotics and their mechanisms of action against antimicrobial resistance.

€ 10.968.734
ERC Starting...

Scalable Microbial Metabolite Discovery Through Synthetic Biology

This project aims to enhance the discovery of microbial secondary metabolites by developing a scalable heterologous expression platform to access untapped biosynthetic genes for drug development.

€ 1.490.250
ERC Proof of...

High throughput development platform for oligonucleotide aptamers

SPARXS is an innovative platform that enables rapid design of affinity probes by simultaneously analyzing binding kinetics and sequences of millions of aptamers for diverse applications.

€ 150.000
ERC Consolid...

dAta-dRiven integrated approaches to CHemIcal safety assessMEnt and Drug dEvelopment

The ARCHIMEDES project aims to revolutionize chemical and drug development by integrating toxicogenomics, AI, and a Knowledge Graph to enhance safety and innovation in a regulatory-compliant manner.

€ 2.000.000

Vergelijkbare projecten uit andere regelingen

EIC Accelerator

Next generation HPC/QC in silico drug discovery platform for de novo design

ATLAS is an advanced in silico drug discovery platform that aims to reduce costs and cycle times by 50%, with plans to generate new drug candidates every 18 months and expand into the US market by 2027.

€ 2.500.000
Mkb-innovati...

Drug Discovery Intelligence

Het project ontwikkelt een AI-gestuurde softwareapplicatie om risico's in de medicijnontwikkeling te verminderen door het voorspellen van therapeutische targets en drug-target interacties.

€ 20.000
EIC Pathfinder

Personalised Adaptive Medicine

The PERAMEDIC project aims to develop a desktop-sized system for personalized polypill formulation using 3D printing and precise dosing to enhance treatment outcomes and patient adherence.

€ 1.726.876
EIC Pathfinder

Accelerated Discovery Nanobody Platform

The ALADDIN project aims to revolutionize therapeutic antibody discovery for cancer by integrating nanobody technology, AI tools, and innovative models to enhance efficiency and reduce reliance on animal testing.

€ 3.315.441
EIC Accelerator

Accelerating the discovery of high-performance electrocatalysts through artificial intelligence and robotics technology

Dunia is transforming electrocatalyst discovery using AI and robotics to accelerate the process by 90% and reduce costs by 60-70%, enabling carbon-neutral production from captured CO2.

€ 2.499.525